Maria Borelius leaves the Board of Active Biotech AB


"We thank Maria for her strong engagement and valuable contribution to the development of Active Biotech. During her time as Board member, the company has developed into one of the most successful biotech companies in Europe. We wish her good luck in her new major challenge", says Mats Arnhög, Chairman of the Board of Active Biotech.
Maria Borelius has served as a Board member of Active Biotech AB since year 2000.
Lund 9 October 2006
Sven Andréasson
President & CEO
Active Biotech AB
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB ( 556223-9227)
P.O. Box 724, SE-220 07 Lund
Tel + 46 46-19 20 00
Fax +46 46-19 20 50